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on mortality associated to ID and CAP, for the base case scenario. It predicts that
vaccines would reduce 11.34 deaths (PCV-13) and 11.03 deaths (PHiD-CV) per
100,000 vaccinated infants. Besides, PHiD-CV would reduce 221 more myringoto-
mies and 3,891 more AOM cases than PCV-13, per 100,000 vaccinated infants. The
direct medical costs averted (undiscounted) due to ID and CAP is similar for both
vaccines. Instead, PHiD-CV would save 1.9 times more AOM medical costs than
PCV-13. Both vaccines are cost effective, but PHiD-CV would generate more QALY
gains (1176 additional QALYs) and in addition, would be cost saving. It was esti-
mated that PHiD-CV requires a reduced annual investment of 10 million (PAHO
prices) or 1.6 million (price parity) US$, compared to PCV-13. CONCLUSIONS: Both
vaccines would reduce significantly the impact of invasive pneumococcal disease
and CAP, but PHiD-CV will generate more QALYs gain and will be cost saving
compared to PCV-13, due to its greater effects over AOM.
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OBJECTIVES: Despite recent progress in our understanding of the economics of
ADHD in children and adolescents, little is known about the comparative cost
effectiveness of treatment strategies for adult ADHD. Even for ADHD in children,
there is a shortage of robust data supporting the cost effectiveness of psychother-
apeutic interventions.METHODS: A randomized, double-blind, placebo-controlled
multicenter study has been initiated in Germany, enrolling 448 adult patients with
ADHD. Patients are assigned to one out of four parallel treatment arms: 1) a struc-
tured disorder tailored psychotherapy (dialectical behavioral therapy, DBT) plus
medication (methylphenidate); 2) DBT and placebo; 3) psychiatric counseling with-
out specific behavioral interventions (clinical management) plus medication; or 4)
clinical management and placebo. DBT and clinical management are administered
weekly for the first 12 weeks and on a four-weekly basis thereafter, until the end of
the one-year-observation period. An additional follow-up investigation is sched-
uled at 18 months after treatment termination. RESULTS: Endpoints include symp-
tomatic improvement (primary endpoint: Conners’ Adult Rating Scale, blind-ob-
server rated), general psychopathology, clinical global impression, and a disorder-
specific quality of life questionnaire. In order to facilitate cost utility analysis,
health-related quality of life is also measured by means of the EQ-5D and SF-36. For
primary analysis, the perspective of Statutory Health Insurance will be adopted;
resource use and costing from a societal perspective will be done for secondary
analyses. Probabilistic sensitivity analyses will be done using nonparametric boot-
strapping on the basis of patient-level study data. CONCLUSIONS: The COMPAS
Study will, for the first time, provide insights into the cost effectiveness of a disor-
der tailored psychotherapy for adult ADHD. Key hypotheses are: 1) that combined
treatment (study arm 1) is more effective than either option (DBT or medication)
alone, both short and long term, and 2) that a tailored psychotherapeutic interven-
tion will meet broadly accepted benchmarks of cost effectiveness.
PIH30
ENDOMETRIOSIS-ASSOCIATED PELVIC PAIN TREATED WITH DIENOGEST OR
GNRH ANALOGUES: COST-UTILITY COMPARISON WITH 5 YEARS TIME
HORIZON
Lukac M1, Knight C2, Bielik J3, Tomek D4, Petri JC5, Bojnicky M1, Kovac A1
1Slovak Medical University, Bratislava, Slovak Republic, 2RTI Health Solutions, Sheffield, UK, UK,
3Trencin University, Trencin, Slovak Republic, 4Slovak Society for Pharmacoeconomics,
Bratislava, Slovak Republic, 5Bayer Schering Pharma AG, Berlin, Germany
OBJECTIVES:To estimate the cost effectiveness of dienogest versus GnRH analogue
(GnRH-a) for the treatment of endometriosis-associated chronic pelvic pain in Slo-
vakia for 5 years time horizon. METHODS: A cost-utility Markov model based on
results of randomized controlled trial (AU19) was adapted to a Slovakian setting.
The AU19 trial, which compared dienogest and GnRH-a (leuprolide) in the treat-
ment of endometriosis-associated chronic pelvic pain over a 6 month period,
showed no statistically significant differences in response rates. The dienogest
annual relapse rate was derived from 52-weeks extension study, while relapse
rates for the GnRH-a were derived from the literature. Local cost data was based on
published price lists, clinical guidelines, product labels and expert opinion. QoL
related utilities were derived from individual patient SF-36 scores from AU19 da-
taset. Effectiveness was measured in quality-adjusted life years (QALY). Time ho-
rizon was set at five years and a payers’ perspective was adopted. Discount rate was
5% per year for both costs and effects according to valid Ministry of Health (MoH)
guidelines for health economic evaluation. Both one-way and probabilistic sensi-
tivity analyses were performed. RESULTS: Dienogest showed that it was cost-ef-
fective compared to a GnRH-a, with an overall cost reduction of 426 € and a QALY
gain of 0.069 per patient. Cost reduction was due to both the differences in the
average drug cost during the two year period and the average laparoscopy cost. In
probabilistic sensitivity analysis 92 % of simulations were below 18,000 €/QALY,
which is the officially published threshold for willingness to pay in Slovakia. In 79%
of cases dienogest treatment was dominant over GnRH-a. CONCLUSIONS: Dieno-
gest is a cost-effective alternative to GnRH analogue for the treatment of endo-
metriosis-associated chronic pelvic pain in a Slovakian setting in a five-year time
horizon.
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OBJECTIVES: The majority of individuals with chronic hepatitis C virus (HCV) are
adults, and there is much experience in Australia with interferon-based treat-
ments in adults using combination pegylated- interferon and ribavirin treatment.
Pegylated-interferon alfa-2b was first approved for adult use in Australia and for
reimbursement in 2003. It is currently reimbursed for initial treatment, and for a
single retreatment course. Nonetheless, a limited number of children and adoles-
cents in Australia contract the disease. Currently these individuals have no regis-
tered or reimbursed approved therapies available to them. This analysis reports a
cost-effectiveness analysis of a single course of initial pegylated-interferon alfa-2b
therapy in paediatrics with a bodyweight of at least 27 kg, reflecting the lowest
dosage that will be supplied in Australia. METHODS: A cost-utility analysis was
conducted using a lifetime Markov model. Analysis of paediatric treatment versus
no treatment was undertaken to determine the impact expansion of reimburse-
ment would have on the cost-effectiveness of the total population. Data were
sourced from a study assessing sustained virological response, and the literature
reporting the natural history and utility weights regarding HCV. RESULTS: Down-
stream cost-offsets associated with treatment reduce the total incremental cost
from AU$13,208 to AU$4767. These cost-offsets arose from avoidance of down-
stream transitions to more severe and costly states of health. Treatment was also
shown to be associated with improvements in health-related quality of life due to
the downstream avoidance of more serious health states as well as the obvious
improvement in viral clearance. Over the lifetime of a patient, the base case anal-
ysis estimated an improvement of approximately 2.01 QALYs, generating an incre-
mental cost-effectiveness ratio of AU$2373 per QALY. CONCLUSIONS: Expanding
reimbursement to include paediatric treatment of chronic HCV is a highly cost-
effective way to equitably treat chronic HCV, regardless of age.
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BACKGROUND: Conducting pediatric studies is complex and the most significant
barrier is infant enrollment by parental consent. This obstacle is currently found
both for healthy and sick infants. The reason for the parents’ refusal to consent is
not obvious and may be due to multiple factors. OBJECTIVES: To identify the fac-
tors influencing parents’ decisions to refuse infant participation in pediatric
studies. METHODS: Observational, transversal study carried out by French phar-
macists randomly selected among the 2,090 pharmacies of the In fine PHARMA®
network (representative of French pharmacies in terms of geographic location and
sales). Parents presenting to participating pharmacies were eligible. Data were
collected through questionnaires fulfilled by participating parents. RESULTS:
Twenty-one pharmacists agreed to participate and enrolled 105 participating par-
ents. Among them, 78 (74%) filled out a questionnaire. Participating families had an
average of 2.3 children, 81% were living in an urban environment, and 51% of the
infants were males. Most of the parents (97%) had never enrolled their children in
a study. Main deterrents to parental consent were: they viewed pediatric studies as
risky (35%), they did not want their infant to be treated as an experimental animal
(20%), their infant was not ill (12%), the information provided by the physician was
too confusing and/or complicated (10%). Parents may have been willing to have
their child participate in a study only if the study was evaluating a new drug, their
child’s participation would further medical research (31%), their child suffered
from a severe illness (24%), and they had great confidence in their physician (22%).
CONCLUSIONS: The results of this survey show that the factors negatively influ-
encing parents’ decisions to consent were the perceived risk presented by the
studies, the lack of interest to medical research if their child was not ill, and the lack
of information about the study.
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OBJECTIVES:Medication nonadherence among patients with chronic conditions is
a significant barrier to achieving therapeutic outcomes. The objective of this study
was to identify patient reported factors and reasons associated with medication
nonadherence. METHODS: Online cross-sectional survey of patients taking medi-
cations for seven chronic conditions: asthma/COPD, bipolar depression, cardiovas-
cular disease, diabetes, neuropathic pain, osteoporosis, and rheumatoid arthritis.
The first 50 patients to respond to the survey for each of the seven conditions were
evaluated (total n350). Patients provided demographic information and answered
questions about their drug therapy including knowledge and satisfaction with their
medications, difficulties in taking their medications, and how often they take their
medication as prescribed. Adherence was defined as patients self-reporting that
they always take their medication as prescribed. Nonadherence was defined as
never, sometimes or often take medications as prescribed. Multivariate logistic
regression was performed to identify patient factors and reasons associated with
nonadherence. RESULTS: Among the 350 patients who completed the survey, the
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